Vericiguat (Verquvo) for Heart Failure

Date: March 8, 2021
Issue #: 
1619Summary: 
The FDA has approved vericiguat (Verquvo– Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptom atic chronic heart failure and left
ventricular ejection fraction (LVEF)<45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat(Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension and
chronic thromboembolic pulmonary hypertension,
was the first.

Source: The Medical Letter - February 9, 2021 Category: Drugs & Pharmacology Authors: admin Source Type: research